Novel CD20 monoclonal antibodies for lymphoma therapy

Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or...

Descripción completa

Detalles Bibliográficos
Autores principales: Cang, Shundong, Mukhi, Nikhil, Wang, Kemeng, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479003/
https://www.ncbi.nlm.nih.gov/pubmed/23057966
http://dx.doi.org/10.1186/1756-8722-5-64
_version_ 1782247380679131136
author Cang, Shundong
Mukhi, Nikhil
Wang, Kemeng
Liu, Delong
author_facet Cang, Shundong
Mukhi, Nikhil
Wang, Kemeng
Liu, Delong
author_sort Cang, Shundong
collection PubMed
description Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin’s lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab).
format Online
Article
Text
id pubmed-3479003
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34790032012-10-24 Novel CD20 monoclonal antibodies for lymphoma therapy Cang, Shundong Mukhi, Nikhil Wang, Kemeng Liu, Delong J Hematol Oncol Review Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin’s lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab). BioMed Central 2012-10-11 /pmc/articles/PMC3479003/ /pubmed/23057966 http://dx.doi.org/10.1186/1756-8722-5-64 Text en Copyright ©2012 Cang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Cang, Shundong
Mukhi, Nikhil
Wang, Kemeng
Liu, Delong
Novel CD20 monoclonal antibodies for lymphoma therapy
title Novel CD20 monoclonal antibodies for lymphoma therapy
title_full Novel CD20 monoclonal antibodies for lymphoma therapy
title_fullStr Novel CD20 monoclonal antibodies for lymphoma therapy
title_full_unstemmed Novel CD20 monoclonal antibodies for lymphoma therapy
title_short Novel CD20 monoclonal antibodies for lymphoma therapy
title_sort novel cd20 monoclonal antibodies for lymphoma therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479003/
https://www.ncbi.nlm.nih.gov/pubmed/23057966
http://dx.doi.org/10.1186/1756-8722-5-64
work_keys_str_mv AT cangshundong novelcd20monoclonalantibodiesforlymphomatherapy
AT mukhinikhil novelcd20monoclonalantibodiesforlymphomatherapy
AT wangkemeng novelcd20monoclonalantibodiesforlymphomatherapy
AT liudelong novelcd20monoclonalantibodiesforlymphomatherapy

Ejemplares similares